Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM

doi:10.1016/j.omto.2019.04.008

	Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM
	Ma, Yu-Shui 1,2,3; Wu, Zhi-Jun 1; Zhang, Hong-Wei4 ; Cai, Bo 5; Huang, Tao 6; Long, Hui-Deng 2; Xu, Hong 7; Zhao, Yong-Zhong 8; Yin, Yu-Zhen 2; Xue, Shao-Bo 2; Li, Liu 2; Liu, Cheng-Lin 9; Xie, Ru-Ting 2; Tian, Lin-Lin 2; Liu, Ji-Bin 10; Wu, Xu-Ming 5; Fu, Da 2
	2019-09-27
发表期刊	MOLECULAR THERAPY-ONCOLYTICS
ISSN	2372-7705
卷号	14 页码:172-178
发表状态	已发表
DOI	10.1016/j.omto.2019.04.008
摘要	Colorectal cancer (CRC) is the third most common cancer worldwide, and liver metastasis presents a major cause of CRC-associated death. Extensive genomic analysis has provided valuable insight into the pathogenesis and progression of CRC; however, a comprehensive proteogenomic characterization of CRC liver metastasis (CLM) has yet to be reported. Here, we analyzed the proteomes of 44 paired normal colorectal tissues and CRC tissues with or without liver metastasis, as well as analyzed genomics of CRC characterized previously by The Cancer Genome Atlas (TCGA) to conduct integrated proteogenomic analyses. We identified a total of 2,170 significantly deregulated proteins associated with CLM, 14.88% of which were involved in metabolic pathways. The mutated peptide number was found to have potential prognosis value, and somatic variants revealed two metabolism-related genes UQCR5 and FDFT1 that frequently mutated only in the liver metastatic cohort and displayed dysregulated protein abundance with biological function and clinical significance in CLM. Proteogenomic characterization and integrative and comparative genomic analysis provides functional context and prognostic value to annotate genomic abnormalities and affords a new paradigm for understanding human colon and rectal cancer liver metastasis.
URL	查看原文
收录类别	SCI ; SCIE
语种	英语
资助项目	Jiangsu 333 Program[BRA2017205]
WOS研究方向	Oncology ; Research & Experimental Medicine
WOS类目	Oncology ; Medicine, Research & Experimental
WOS记录号	WOS:000488089600016
出版者	CELL PRESS
WOS关键词	PROTEOGENOMIC CHARACTERIZATION ; HUMAN COLON ; CANCER ; PATHWAY ; CELLS ; PROLIFERATION ; SENSITIVITY ; STERNNESS
原始文献类型	Article
引用统计
文献类型	期刊论文
条目标识符	https://kms.shanghaitech.edu.cn/handle/2MSLDSTB/80401
专题	免疫化学研究所_公共科研平台_分析化学平台
通讯作者	Liu, Ji-Bin; Wu, Xu-Ming; Fu, Da
作者单位	1.Nantong Tumor Hosp, Dept Radiotherapy, Nantong 226631, Peoples R China 2.Tongji Univ, Shanghai Peoples Hosp 10, Cent Lab Med Res, Sch Med, Shanghai 200072, Peoples R China 3.East China Normal Univ, Coll Chem & Mol Engn, Shanghai Engn Res Ctr Mol Therapeut & New Drug De, Shanghai 200062, Peoples R China 4.ShanghaiTech Univ, Shanghai Inst Adv Immunochem Studies, Analyt Chem Platforms, Shanghai 201210, Peoples R China 5.Nantong Ctr Dis Control & Prevent, Dept Chron Dis, Nantong 226007, Peoples R China 6.Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Hlth Sci, Shanghai 200025, Peoples R China 7.Hangzhou Red Cross Hosp, Dept Gastroenterol & Hepatol, Hangzhou 310003, Zhejiang, Peoples R China 8.Southern Med Univ, Dept Med Genet, Guangzhou 510515, Guangdong, Peoples R China 9.Shanghai Jiao Tong Univ, Sch Life Sci & Biotechnol, Shanghai 200240, Peoples R China 10.Nantong Tumor Hosp, Canc Inst, Nantong 226631, Peoples R China
推荐引用方式 GB/T 7714	Ma, Yu-Shui,Wu, Zhi-Jun,Zhang, Hong-Wei,et al. Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM[J]. MOLECULAR THERAPY-ONCOLYTICS,2019,14:172-178.
APA	Ma, Yu-Shui.,Wu, Zhi-Jun.,Zhang, Hong-Wei.,Cai, Bo.,Huang, Tao.,...&Fu, Da.(2019).Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM.MOLECULAR THERAPY-ONCOLYTICS,14,172-178.
MLA	Ma, Yu-Shui,et al."Dual Regulatory Mechanisms of Expression and Mutation Involving Metabolism-Related Genes FDFT1 and UQCR5 during CLM".MOLECULAR THERAPY-ONCOLYTICS 14(2019):172-178.